Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451288 | 0.83 | KMT2A (0.46) | OPRM1OPRD1OPRK1OPRL1L3MBTL3 | |
| SCHEMBL24359355 | 0.83 | KMT2A (0.46) | OPRM1OPRD1OPRK1OPRL1L3MBTL3 | |
| SCHEMBL9063099 | 0.83 | L3MBTL3 (0.42) | OPRM1OPRD1OPRK1OPRL1L3MBTL3 | |
| SCHEMBL11461803 | 0.82 | SLC18A2 (0.45) | CYP1A2CYP2D6HIF1A | |
| SCHEMBL14458306 | 0.78 | CYP1A2 (0.43) | OPRM1OPRD1OPRK1OPRL1L3MBTL3 | |
| SCHEMBL6079285 | 0.78 | DPP4 (0.41) | — | |
| SCHEMBL4727655 | 0.77 | KDM4E (0.41) | OPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL2883224 | 0.77 | KDM4E (0.41) | OPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL29046165 | 0.77 | CHRM3 (0.47) | CYP1A2CYP2D6KMT2A | |
| SCHEMBL24359261 | 0.76 | KMT2A (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | OPRM1 1194/4885OPRD1 1921/4885OPRK1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.